Literature DB >> 18182036

Selectin haplotypes and the risk of venous thrombosis: influence of linkage disequilibrium with the factor V Leiden mutation.

S Uitte de Willige1, M C H De Visser, H L Vos, J J Houwing-Duistermaat, F R Rosendaal, R M Bertina.   

Abstract

BACKGROUND: Selectins (E-, L- and P-selectin) and their most important counter-receptor P-selectin glycoprotein ligand (SELPLG) facilitate the interaction of platelets, leukocytes and endothelial cells at inflammatory sites. Selectin polymorphisms/haplotypes have been associated with cardiovascular disease.
OBJECTIVES: We investigated the association between haplotypes (H) of these four genes and deep venous thrombosis (DVT) risk. We additionally explored the effect of linkage disequilibrium (LD) with the nearby Factor V Leiden mutation (FVL). Furthermore, interactions between SELPLG polymorphisms and selectin polymorphisms were investigated. PATIENTS/
METHODS: Leiden Thrombophilia Study (LETS) subjects were genotyped for 24 polymorphisms by TaqMan or PCR-RFLP, detecting all common haplotypes in four blocks. P-selectin was analyzed in two blocks, upstream (SELPup) and downstream (SELPdown) of the recombination hotspot.
RESULTS: In E- and L-selectin, none of the haplotypes was associated with DVT risk. In SELPup, H2-carriers had a 1.3-fold increased risk (95% CI, 1.0-1.7), whereas H4-carriers had a 1.4-fold decreased risk (95% CI, 0.5-1.0). In SELPdown, H2-carriers had a 1.3-fold increased risk (95% CI, 1.0-1.7). Because of LD with FVL, we subsequently excluded all FVL-carriers and all risks disappeared. Mutual adjustment within a logistic regression model resulted in disappearance of the risks for the SELP haplotypes, whereas FVL risk remained.
CONCLUSIONS: After adjustment for LD with FVL, none of the selectin haplotypes was associated with DVT risk, showing that the increased risks of the selectin haplotypes were a reflection of the effect of FVL on thrombosis risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18182036     DOI: 10.1111/j.1538-7836.2007.02879.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

1.  Deep vein thrombosis: related to anemophilous pollen?

Authors:  Bin Zhou; Yiqing Li; Dan Shang; Yiping Dang; Weici Wang; Shi Sheng; Xianghai Kong; Bi Jin
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

2.  The Thr715Pro variant impairs terminal glycosylation of P-selectin.

Authors:  Hariharan Subramanian; Stepan Gambaryan; Simon Panzer; Thomas Gremmel; Ulrich Walter; Christine Mannhalter
Journal:  Thromb Haemost       Date:  2012-09-26       Impact factor: 5.249

3.  Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism.

Authors:  J A Heit; J M Cunningham; T M Petterson; S M Armasu; D N Rider; M DE Andrade
Journal:  J Thromb Haemost       Date:  2011-06       Impact factor: 5.824

Review 4.  Biomarkers of deep venous thrombosis.

Authors:  Huacheng Hou; Zhijuan Ge; Pu Ying; Jin Dai; Dongquan Shi; Zhihong Xu; Dongyang Chen; Qing Jiang
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

5.  A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q.

Authors:  J A Heit; S M Armasu; Y W Asmann; J M Cunningham; M E Matsumoto; T M Petterson; M De Andrade
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

6.  Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis.

Authors:  Knut Anders Mosevoll; Roald Lindås; Oystein Wendelbo; Oystein Bruserud; Håkon Reikvam
Journal:  Springerplus       Date:  2014-09-30

Review 7.  Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis.

Authors:  Knut A Mosevoll; Silje Johansen; Øystein Wendelbo; Ina Nepstad; Øystein Bruserud; Håkon Reikvam
Journal:  Front Med (Lausanne)       Date:  2018-05-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.